GSK plc (LON:GSK) Given Average Rating of “Hold” by Brokerages

GSK plc (LON:GSK) has received an average rating of “Hold” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is GBX 2,048.57.

Several research firms recently commented on GSK. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th.

Insider Transactions at GSK

In other news, insider Jonathan Symonds purchased 1,550 shares of GSK stock in a transaction that occurred on Friday, June 19th. The stock was acquired at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Also, insider Jeannie Lee bought 802 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was bought at an average price of GBX 5,069 per share, with a total value of £40,653.38. Insiders have purchased 3,618 shares of company stock valued at $13,481,942 over the last three months. Company insiders own 0.20% of the company’s stock.

GSK Trading Down 1.1%

LON:GSK opened at GBX 1,846.50 on Friday. GSK has a 52-week low of GBX 1,445 and a 52-week high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. The stock has a fifty day simple moving average of GBX 1,920.49 and a 200-day simple moving average of GBX 1,983.22. The company has a market capitalization of £73.96 billion, a PE ratio of 15.67, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities research analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.